TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25830422

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1044
Study: 23152373

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/day
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 21778599

Group type: EXPERIMENTAL
Intervention: Overpressed ceramics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Layered ceramics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Layered ceramics (LV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Layered ceramics (LC)
Number of subjects: 0
Study: 19428394

Group type: EXPERIMENTAL
Intervention: Reboxetine (RBX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16886238

Group type: EXPERIMENTAL
Intervention: HCV grading and staging using the Batts and Ludwig schema
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: ACR global grading using the 1997 Banff schema
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Rejection activity index scoring of ACR
Number of subjects: 312
Study: 15685825

Group type: EXPERIMENTAL
Intervention: Gemcitabine in combination with paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0
Study: 11723016

Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg/d) for 7 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pl(A2) carriers (no aspirin effect)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pl(A1A1) subjects (after aspirin ingestion)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pl(A2) carriers (after aspirin ingestion)
Number of subjects: 24
Study: 9220211

Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution (200 mg once daily)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Clotrimazole troches (10 mg five times daily)
Number of subjects: 162
Study: 8253932

Group type: EXPERIMENTAL
Intervention: Percoll separation
Number of subjects: 0
Study: 3552007

Group type: EXPERIMENTAL
Intervention: Intermittent positive pressure ventilation (IPPV) with nitrous oxide in oxygen facilitated by atracurium 0.5 mg kg‐1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Spontaneous ventilation (SV) technique with halothane and nitrous oxide in oxygen
Number of subjects: 50
Study: 29699816

Group type: EXPERIMENTAL
Intervention: Weight gain prevention strategies (small changes to diet and physical activity)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Weight gain prevention strategies (large changes)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 524
Study: 27524193

Group type: EXPERIMENTAL
Intervention: Four-channel FES treatment based on normal gait pattern
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Single-channel FES treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo electrical group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: All groups (four-channel, single-channel, placebo)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Four-channel FES group
Number of subjects: 58
Study: 25012235

Group type: EXPERIMENTAL
Intervention: Targeted, theory‐ and evidence‐informed implementation intervention including local stakeholder meetings, identification of nursing and medical opinion leaders, a train‐the‐trainer day, and standardized education and interactive workshops over 3 months.
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Passive dissemination of clinical practice guidelines (control group).
Number of subjects: 1020
Study: 23729106

Group type: EXPERIMENTAL
Intervention: Allergic rhinitis and nasal polyps (SP-D and IL-16 expression)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (inferior turbinate mucosa)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Allergic rhinitis
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nasal polyps
Number of subjects: 45
Study: 20089454

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) 1.2 g/d for 5 days starting at day 3 of the cycle for 12 consecutive cycles
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 5 days starting at day 3 of the cycle for 12 consecutive cycles
Number of subjects: 60
Study: 18166533

Group type: EXPERIMENTAL
Intervention: Multifaceted, community‐wide intervention including physician behavior‐change strategy, guideline dissemination, small‐group education, updates, educational materials, and prescribing feedback.
Number of subjects: 223135

Group type: EXPERIMENTAL
Intervention: Multifaceted, community‐wide intervention
Number of subjects: 223135

Group type: COMPARATOR
Intervention: None (baseline data)
Number of subjects: 223135
Study: 16054578

Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12849770

Group type: EXPERIMENTAL
Intervention: Hemispherectomy patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 22
Study: 10372705

Group type: EXPERIMENTAL
Intervention: MK-677 (25 mg daily for 8 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 24
Study: 8879912

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for bulimia nervosa
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Presence of mood disorder
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Presence of anxiety disorder
Number of subjects: 114
Study: 1906042

Group type: EXPERIMENTAL
Intervention: Long course of ampicillin (7 days)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Short course of ampicillin (three doses)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 6349401

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 30761509

Group type: EXPERIMENTAL
Intervention: Cilostazol + Donepezil
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo + Donepezil
Number of subjects: 36
Study: 30114721

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 20
Study: 27685609

Group type: EXPERIMENTAL
Intervention: Composite fluoride intervention (varnish with 22,600 p.p.m. fluoride, toothbrush, toothpaste with 1450 p.p.m. fluoride, and prevention advice every 6 months for 3 years)
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: Composite fluoride intervention
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Control group (prevention advice alone)
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1248
Study: 24515422

Group type: EXPERIMENTAL
Intervention: Community health worker intervention
Number of subjects: 446
Study: 22314392

Group type: EXPERIMENTAL
Intervention: Amitriptyline (exact dosage and duration not specified)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Recall of symptoms
Number of subjects: 63
Study: 20140275

Group type: EXPERIMENTAL
Intervention: Bacillus coagulans GBI‐30, 6086
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 17521243

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telmisartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of telmisartan and nisoldipine
Number of subjects: 0
Study: 15186950

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 27
Study: 11777359

Group type: EXPERIMENTAL
Intervention: 10 mg of oral prednisone per day
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 9696213

Group type: EXPERIMENTAL
Intervention: Step-down regimen with FSH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard protocol
Number of subjects: 0
Study: 8122593

Group type: EXPERIMENTAL
Intervention: Cilazapril after angioplasty
Number of subjects: 653

Group type: COMPARATOR
Intervention: Static criterion of > 50% diameter stenosis at follow-up
Number of subjects: 653

Group type: COMPARATOR
Intervention: Dynamic criteria of > or = 0.40 or > or = 0.72 mm change in minimal lumen diameter
Number of subjects: 653

Group type: COMPARATOR
Intervention: Percentage diameter stenosis measurements
Number of subjects: 653
Study: 2764533

Group type: EXPERIMENTAL
Intervention: Cefoperazone (CPZ)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral neomycin-erythromycin
Number of subjects: 24

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 24
Study: 1026543

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amylobarbitone sodium 200 mg
Number of subjects: 0
Study: 31564410

Group type: EXPERIMENTAL
Intervention: [11C]telmisartan with predosing of 80 mg telmisartan (two 40 mg Micardis® tablets)
Number of subjects: 8

Group type: COMPARATOR
Intervention: [11C]telmisartan without predosing
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: [11C]telmisartan with predosing of 80 mg telmisartan
Number of subjects: 8
Study: 28153828

Group type: EXPERIMENTAL
Intervention: CZP+MTX
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: CZP+MTX→MTX
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: CZP
Number of subjects: 159

Group type: COMPARATOR
Intervention: CZP+MTX and PBO+MTX
Number of subjects: 159
Study: 25494952

Group type: EXPERIMENTAL
Intervention: VR simulator
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 8
Study: 23758821

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa or rFSH treatment flexibility options
Number of subjects: 0

Group type: COMPARATOR
Intervention: Starting ovarian stimulation on cycle day 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Receiving hCG on the day the hCG criterion was met
Number of subjects: 0

Group type: COMPARATOR
Intervention: Receiving rFSH on the day of hCG administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reduced versus fixed-dose of rFSH from day 8
Number of subjects: 0
Study: 20737175

Group type: EXPERIMENTAL
Intervention: TAI using lipiodol (n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: TAI using DSM (n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: TAI using lipiodol and DSM (n = 15)
Number of subjects: 45
Study: 18086142

Group type: EXPERIMENTAL
Intervention: ParaPost/CoJet
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: FibreKleer/AlOxide
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ParaPost/AlOxide
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: FibreKleer/CoJet
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: FibreKor/AlOxide
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ParaPost/Unroughened
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: FibreKor/CoJet
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: FibreKor/Unroughened
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: FibreKleer/Unroughened
Number of subjects: 90
Study: 17320192

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 23
Study: 16200447

Group type: EXPERIMENTAL
Intervention: Trabeculectomy (TE)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Viscocanalostomy (VCO)
Number of subjects: 22
Study: 11359224

Group type: EXPERIMENTAL
Intervention: 15 mL NS x 1 (n = 10)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 15 mL NS x 2 (n = 12)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (n = 11)
Number of subjects: 33
Study: 9387180

Group type: EXPERIMENTAL
Intervention: Silicone oil
Number of subjects: 34

Group type: COMPARATOR
Intervention: SF6
Number of subjects: 34
Study: 7524278

Group type: EXPERIMENTAL
Intervention: estramustine phosphate
Number of subjects: 62

Group type: COMPARATOR
Intervention: non-steroidal symptomatic treatment
Number of subjects: 62
Study: 3063290

Group type: EXPERIMENTAL
Intervention: Active vitamin D (alphacalcidol), 1 microgram daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 31121100

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Combined exercise training
Number of subjects: 143

Group type: COMPARATOR
Intervention: Diet-only control
Number of subjects: 143
Study: 31579037

Group type: EXPERIMENTAL
Intervention: Aquablation using the Aquabeam system (PROCEPT BioRobotics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: TURP (Transurethral Resection of the Prostate)
Number of subjects: 0
Study: 29233906

Group type: EXPERIMENTAL
Intervention: Sleep restriction (SR) - 50% of habitual sleep duration for 2 nights
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON) - habitual sleep for 2 nights
Number of subjects: 10
Study: 23265332

Group type: EXPERIMENTAL
Intervention: Angiographic complete revascularization (CR) in PCI arm (52.8%)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Angiographic complete revascularization (CR) in CABG arm (66.9%)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Incomplete revascularization (ICR)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Presence of total occlusions (TO)
Number of subjects: 1800
Study: 21235416

Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) 3 g/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: KRG and Placebo
Number of subjects: 80
Study: 18698316

Group type: EXPERIMENTAL
Intervention: Betahistine 48 mg (n=23)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 281
Study: 17070197

Group type: EXPERIMENTAL
Intervention: Evaluation while off any estrogen therapy
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Physiologic transdermal E(2) therapy
Number of subjects: 130
Study: 12590030

Group type: EXPERIMENTAL
Intervention: Once-daily tramadol tablets 150 mg
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Once-daily tramadol tablets 200 mg
Number of subjects: 134

Group type: COMPARATOR
Intervention: Normal release tramadol capsules 50 mg 8-hourly
Number of subjects: 134
Study: 10767191

Group type: EXPERIMENTAL
Intervention: MRI staging before radiotherapy
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: MRI features (tumour size, circumferential tumour extent, presence of hydronephrosis)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: MRI T stage
Number of subjects: 143
Study: 8838693

Group type: EXPERIMENTAL
Intervention: Self-exposure to both internal (interoceptive) and external cues
Number of subjects: 26

Group type: COMPARATOR
Intervention: Self-exposure to external cues only
Number of subjects: 26
Study: 1441953

Group type: EXPERIMENTAL
Intervention: Continuous irrigation with Ringer solution during cement curing
Number of subjects: 19

Group type: COMPARATOR
Intervention: No irrigation (control group)
Number of subjects: 19
Study: 3913478

Group type: EXPERIMENTAL
Intervention: Mianserin (30 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amitryptiline (75 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine (75 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maprotiline (75 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31873085

Group type: EXPERIMENTAL
Intervention: Urine cloudiness
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Increased discriminatory scale for urine cloudiness (turbidity)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Urinary levels of MMP9, NGAL, CXCL8, and IL-1β
Number of subjects: 17
Study: 30124585

Group type: EXPERIMENTAL
Intervention: Lamotrigine (titrated to 200 mg/d)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 27585503

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 1305

Group type: COMPARATOR
Intervention: Coronary Artery Bypass Graft (CABG)
Number of subjects: 1305
Study: 25217073

Group type: EXPERIMENTAL
Intervention: senofilcon A (Acuvue Oasys)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: lotrafilcon A (Air Optix)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: balafilcon A (Purevision)
Number of subjects: 54
Study: 22145959

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 459
Study: 19796716

Group type: EXPERIMENTAL
Intervention: Calcium carbonate tablets providing elemental calcium at 63 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Calcium carbonate tablets providing elemental calcium at 354 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Calcium carbonate tablets providing elemental calcium at 660 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Calcium carbonate tablets providing elemental calcium at 966 mg/day
Number of subjects: 80
Study: 17460023

Group type: EXPERIMENTAL
Intervention: Fluconazole prophylaxis (6 mg/kg for 3 weeks, administered orally when enteral feeding achieved)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Fluconazole prophylaxis
Number of subjects: 110
Study: 15659584

Group type: EXPERIMENTAL
Intervention: HIV-prevention curriculum
Number of subjects: 279

Group type: COMPARATOR
Intervention: Health maintenance curriculum
Number of subjects: 279
Study: 11837732

Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10361177

Group type: EXPERIMENTAL
Intervention: Pylorus-preserving pancreaticoduodenectomy (PPPD)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Whipple procedure
Number of subjects: 31

Group type: COMPARATOR
Intervention: Comparison of both procedures
Number of subjects: 31
Study: 8832526

Group type: EXPERIMENTAL
Intervention: Combined therapy including prednisone plus interferon (3 Mu/day induction, 3 Mu three times a week maintenance)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Prednisone therapy
Number of subjects: 33
Study: 2076622

Group type: EXPERIMENTAL
Intervention: naproxen gel (10%)
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo gel (base alone)
Number of subjects: 120
Study: 6243531

Group type: EXPERIMENTAL
Intervention: 1 g cephaloridine
Number of subjects: 300

Group type: COMPARATOR
Intervention: Polybactrin aerosol
Number of subjects: 300
Study: 31204532

Group type: EXPERIMENTAL
Intervention: Blood group O
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Blood group O with family history of DM
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Blood group O without family history of DM
Number of subjects: 600
Study: 31621150

Group type: EXPERIMENTAL
Intervention: Oral tofacitinib (TOFA)
Number of subjects: 9
Study: 30077185

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg subcutaneously every 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg subcutaneously every 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26747850

Group type: EXPERIMENTAL
Intervention: New-generation drug-eluting stents (DES)
Number of subjects: 10449

Group type: COMPARATOR
Intervention: Early-generation drug-eluting stents (DES)
Number of subjects: 10449
Study: 24077383

Group type: EXPERIMENTAL
Intervention: PPDC
Number of subjects: 9

Group type: COMPARATOR
Intervention: CONT
Number of subjects: 9
Study: 21538537

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (extended-release) at doses of 50-300 mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quetiapine IR (immediate-release) at doses of 25-300 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quetiapine IR
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 100
Study: 19279424

Group type: EXPERIMENTAL
Intervention: Topical 0.2 percent glyceryl trinitrate (GTN) ointment
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 69
Study: 17258439

Group type: EXPERIMENTAL
Intervention: Refined Nigrovic rule (Meningitest) applied to internal validation set
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Refined Nigrovic rule (Meningitest) applied to derivation set
Number of subjects: 168
Study: 15237013

Group type: EXPERIMENTAL
Intervention: Uterine depletion procedure followed by myomectomy (group II)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Myomectomy only (group I)
Number of subjects: 486
Study: 11881906

Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Older adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Processing speed and working memory measures
Number of subjects: 0
Study: 10367032

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 microgram/day)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 145
Study: 7547096

Group type: EXPERIMENTAL
Intervention: Tenidap sodium 120 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2262646

Group type: EXPERIMENTAL
Intervention: Salbutamol (0.2 mg, four times a day) and inhaled beclomethasone dipropionate (BDP, 0.5 mg, four times a day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Salbutamol (0.2 mg, four times a day)
Number of subjects: 25
Study: 445785

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30670158

Group type: EXPERIMENTAL
Intervention: Sleep restriction (elimination of 1 hour of sleep relative to the baseline habitual sleep duration)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (exposure to a lamp with no known therapeutic effect)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sleep restriction
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 29158665

Group type: EXPERIMENTAL
Intervention: Single dose of MB12066 (10, 30, 100, 150, 200, 300, or 400 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple doses of MB12066 (100 or 200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0